Haji Shotaro, Miyamoto Ryosuke, Morino Hiroyuki, Osaki Yusuke, Tsuji Seijiro, Nishino Ichizo, Abe Masahiro, Izumi Yuishin
From the Department of Neurology (S.H., R.M., Y.O., Y.I.), Tokushima University Graduate School of Biomedical Sciences; Department of Clinical Neuroscience and Therapeutics (H.M.), Graduate School of Biomedical and Health Sciences; Department of Hematology (S.T., M.A.), Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences; Department of Neuromuscular Research (I.N.), National Institute of Neuroscience, National Centre of Neurology and Psychiatry; and Department of Clinical Genome Analysis (I.N.), Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
Neurol Genet. 2023 May 9;9(3):e200070. doi: 10.1212/NXG.0000000000200070. eCollection 2023 Jun.
Autosomal recessive spinocerebellar ataxia type 9 (SCAR9) has received attention due to its potential response to coenzyme Q10 (CoQ10) supplementation; however, the response has so far been limited and variable.
We report a SCAR9 patient with severe hypophosphatemia who responded well to CoQ10 and phosphate repletion.
A 70-year-old man (the offspring of a consanguineous marriage) presented with cerebellar ataxia and intense fatigue after exercise. Whole-exome sequencing identified a novel homozygous deletion mutation (NM_020247.5:c.1218_1219del) in . We thus diagnosed him with SCAR9. Supplementation of CoQ10 alleviated his symptoms, with the Scale for the Assessment and Rating of Ataxia (SARA) dropping from 16 to 14. During the course of the disease, he demonstrated continuous hypophosphatemia caused by renal phosphate wasting. Gait dysfunction due to weakness and eye movement was partially alleviated, and SARA dropped from 17 to 13 after phosphate repletion.
Phosphate repletion should be considered for patients with severe hypophosphatemia without any apparent subjective symptoms. In this case, phosphate repletion could have improved myopathy leading to partial improvement in the patient's symptoms. Further analyses regarding the association between COQ8A mutation and phosphate wasting are required to elucidate the detailed pathogenesis.
This provides Class IV evidence. This is a single observational study without controls.
常染色体隐性遗传性9型脊髓小脑共济失调(SCAR9)因其对辅酶Q10(CoQ10)补充治疗可能产生反应而受到关注;然而,迄今为止,这种反应有限且存在个体差异。
我们报告了1例SCAR9患者,该患者患有严重低磷血症,对CoQ10和补充磷酸盐反应良好。
一名70岁男性(近亲结婚的后代)出现小脑共济失调,运动后极度疲劳。全外显子组测序在 中发现了一个新的纯合缺失突变(NM_020247.5:c.1218_1219del)。因此,我们诊断他患有SCAR9。补充CoQ10可缓解其症状,共济失调评估和分级量表(SARA)评分从16降至14。在疾病过程中,他因肾性磷酸盐消耗出现持续性低磷血症。补充磷酸盐后,因肌无力和眼球运动导致的步态功能障碍得到部分缓解,SARA评分从17降至13。
对于无明显主观症状的严重低磷血症患者,应考虑补充磷酸盐。在本病例中,补充磷酸盐可能改善了肌病,从而使患者症状得到部分改善。需要进一步分析COQ8A突变与磷酸盐消耗之间的关联,以阐明详细的发病机制。
本研究提供IV级证据。这是一项无对照的单病例观察性研究。